Tag: CAR T

Servier Picked Yposkesi for Lentiviral Vector GMP-manufacturing in CAR-T Cell Development Technology...

cells
Servier, an international independent pharmaceutical company, and Yposkesi, a leading CDMO for gene therapy viral vector manufacturing, announced that they have signed a manufacturing service agreemen...

Biocartis and Kite in Master Development and Commercialization Agreement

Biocartis Group NV, an innovative molecular diagnostics company (Euronext Brussels: BCART), today announced that it has entered into a Master Development and Commercialization Agreement with Kite, a G...

Lonza and Largest Mideast Hospital Facilitate Patient Access to Immunotherapies

Collaboration to assess automated CAR-T cell therapy manufacturing at the point-of-care. Sheba Medical Center at Tel Hashomer, the largest hospital in Israel and the Middle East region, and Swiss-b...

Cellectis to Build New GMP Facilities

Cellectis, a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that it has entered into a lease agreement to build an 82,00...

Gilead’s Kite and MaxCyte in Multi-Drug Clinical Agreement

MaxCyte, the global cell-based medicines and life sciences company, announced that it has expanded its relationship with Kite, a Gilead Company, by entering into a multi-drug clinical and commercial a...

Allogene into Lease Agreement for Building Cell Therapy Facility

Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, announced that it has entered into a lease agreeme...

CMS Proposed Coverage of New Form of Cancer Therapy

Proposed decision would provide nationwide consistency in CMS’s coverage of the innovative new cancer therapy, to improve patient access and ensure appropriate evidence generation. The Centers for ...

NICE Approved Novartis’ DLBCL Drug for Non-Responding Patients

NICE has approved Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) for diffuse large B-cell lymphoma (DLBCL) in adults who did not respond to two or more previous treatments. The drug will be fun...

Brexit Could Hinder Access to CAR-T Therapies across Europe

Brexit and the rise of nationalism in Europe could hinder patients’ access to pricey CAR-T therapies across Europe, a conference heard. In England, the NHS, NICE and the government have joined forc...

Searching for CAR-T Combinations to Tackle Tumours

Getting CAR-T cells to work in solid tumours is proving a tough nut to crack – and a conference heard details of a cutting-edge approach that could inform clinical trials in the future. Kisaco Rese...

TCB Made First Allogeneic GDT Cell Banks

The first completed bio-banks will be used to develop more cost-effective, safe and efficacious cancer treatments. TC BioPharm (TCB), a developer of CAR-T immuno-oncology products, including Gamma ...

Eli Lilly Will not Develop CAR-Ts Now

Eli Lilly’s CEO David Ricks could sign more deals to strengthen its pipeline of cancer drugs, but is leaving gene cell-based CAR-T oncology drugs and rare disease gene therapies for others to develop....

Novartis to Strengthen Cell and Gene Manufacturing Capabilities

Following its success in the burgeoning area of CAR-T therapies, Novartis is looking to strengthen its cell and gene manufacturing capabilities by offering to acquire CDMO CellforCure, manufacturers o...